Picture of Zymeworks logo

ZYME — Zymeworks News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousMid CapMomentum Trap

Zymeworks Inc expected to post a loss of 29 cents a share - Earnings Preview

* Zymeworks Inc  ZYME.OQ   ZYME.O  is expected to show a
fall in
quarterly revenue when it reports  results on May 2 for the
period ending March 31 2024
    * The Middletown Delaware-based  company is expected to
report a
51.0% decrease in revenue to $17.431 million from $35.58 million
a year ago, according to the mean estimate from 6 analysts,
based on LSEG data.
    * ​LSEG's mean analyst estimate for Zymeworks Inc is for a
loss
of 29 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," 3
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts had risen by
about 0.3%
in the last three months. ​
    * Wall Street's median 12-month price target for Zymeworks
Inc is
$14.60​, above​ its last closing price of $8.58. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Dec. 31 2023  -0.46       -0.43      -0.20     Beat    53.9
 Jan. 1 2023   -0.50       -0.47      -0.41     Beat    12.7
 Jan. 1 0001   -0.49       -0.47      -0.76     Missed  -61.6​
 Mar. 31 2023  -0.55       -0.54      -0.36     Beat    32.9
 ​​Dec.        4.44        4.84       4.65      Missed  -3.9
 31 2022                                                
 Sep. 30 2022  -0.91       -0.92      -0.72     Beat    21.8​
 Jun. 30 2022  -0.94       -0.96      -0.97     Missed  -0.7
 Jan. 1 0001   -1.37       -1.67      -1.03     Beat    38.2
 This summary was machine generated April 30 at 23:39 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)

Recent news on Zymeworks

See all news